UAMS Myeloma Institute Revenue and Competitors
Estimated Revenue & Valuation
- UAMS Myeloma Institute's estimated annual revenue is currently $8M per year.
- UAMS Myeloma Institute's estimated revenue per employee is $216,000
Employee Data
- UAMS Myeloma Institute has 37 Employees.
- UAMS Myeloma Institute grew their employee count by 3% last year.
UAMS Myeloma Institute's People
Name | Title | Email/Phone |
---|---|---|
1 | Graduate Assistant | Reveal Email/Phone |
2 | Assistant Professor | Reveal Email/Phone |
UAMS Myeloma Institute Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $8.9M | 41 | -7% | N/A | N/A |
#2 | $155.6M | 461 | -2% | N/A | N/A |
#3 | $8.6M | 40 | -13% | N/A | N/A |
#4 | $7.3M | 34 | -13% | N/A | N/A |
#5 | $8.6M | 40 | 8% | N/A | N/A |
#6 | $81.7M | 275 | -1% | N/A | N/A |
#7 | $12.6M | 52 | 6% | N/A | N/A |
#8 | $60.6M | 204 | 6% | N/A | N/A |
#9 | $18M | 74 | 10% | N/A | N/A |
#10 | $28.6M | 106 | 5% | N/A | N/A |
What Is UAMS Myeloma Institute?
The Myeloma Institute at the University of Arkansas for Medical Sciences is an international leader in the treatment and research of multiple myeloma and related plasma cell disorders. Patients travel from every state in the United States and from more than 50 countries to receive the latest and most promising treatments in Little Rock, Arkansas. Our clinicians and scientists used advanced knowledge of cancer biology and the latest genomic tools to develop new and targeted treatment strategies to increase survival, cure disease, and improve the quality of life for patients around the globe.
keywords:N/AN/A
Total Funding
37
Number of Employees
$8M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8M | 37 | 0% | N/A |
#2 | $3.8M | 37 | 16% | N/A |
#3 | N/A | 37 | 363% | N/A |
#4 | $35M | 37 | -3% | N/A |
#5 | $4.4M | 37 | 6% | N/A |